ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Trifluoroacetic acid → N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetamide

HRID 592240
印刷

反応式

HRID 592240 の反応式
[F:1][C:2]1[CH:3]=[C:4]([CH2:15][C:16]([O:18]C(C)(C)C)=O)[CH:5]=[CH:6][C:7]=1[C:8]1[CH:13]=[CH:12][N:11]=[C:10]([F:14])[CH:9]=1.C(O)(C(F)(F)F)=O.FC1C=C(CC(O)=O)C=CC=1C1C=CN=C(F)C=1.[NH2:48][C:49]1[N:54]=[CH:53][C:52]([N:55]2[CH2:60][CH2:59][N:58]([C:61](=[O:63])[CH3:62])[CH2:57][CH2:56]2)=[CH:51][CH:50]=1.CCN(C(C)C)C(C)C.F[P-](F)(F)(F)(F)F.N1(OC(N(C)C)=[N+](C)C)C2N=CC=CC=2N=N1>C(Cl)Cl.CN(C=O)C>[C:61]([N:58]1[CH2:57][CH2:56][N:55]([C:52]2[CH:51]=[CH:50][C:49]([NH:48][C:16](=[O:18])[CH2:15][C:4]3[CH:5]=[CH:6][C:7]([C:8]4[CH:13]=[CH:12][N:11]=[C:10]([F:14])[CH:9]=4)=[C:2]([F:1])[CH:3]=3)=[N:54][CH:53]=2)[CH2:60][CH2:59]1)(=[O:63])[CH3:62]
参加物実験手順後処理出典と根拠反応ノート

参加物

9

反応物 6

HCID 6422Trifluoroacetic acidHCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 284116891-(4-(6-Aminopyridin-3-YL)piperazin-1-YL)ethan-1-oneHCID 584476772-(3-Fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetic acid
HCID 58447777
Tert-butyl 2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetate

生成物 1

HCID 58447812N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetamide

試薬・触媒・溶媒 2

HCID 6228Dimethylformamide溶媒HCID 6344Dichloromethane溶媒

実験手順

A mixture of tert-butyl 2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetate 207-5 (100 mg, 0.33 mmol) and TFA (0.5 mL) in DCM (3 mL) was stirred at room temperature for 5 hours. The solvents were evaporated to dryness under high vacuum. The crude product, 2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetic acid 207-6 (50 mg, 0.20 mmol), was dissolved in DMF (2 mL), 1-(4-(6-aminopyridin-3-yl)piperazin-1-yl)ethanone (53 mg, 0.24 mmol) and DIEA (174 uL, 1.0 mmol) were added to the solution before O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (114 mg, 0.30 mmol). The mixture was stirred at room temperature overnight. The solvent was removed by rotary evaporation. The crude product was purified by reverse phase HPLC to give N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)acetamide 207. MS m/z 452.2 (M+1); 1H NMR 400 MHz (MeOD) δ 8.21 (d, 1H), 7.96 (d, 1H), 7.88 (d, 1H), 7.57-7.51 (m, 1H), 7.48-7.45 (m, 1H), 7.37 (dd, 1H), 7.30-7.21 (m, 3H), 3.75 (s, 2H), 3.68 (t, 2H), 3.63 (t, 2H), 3.14 (t, 2H), 3.09 (t, 2H, J=5.2 Hz), 2.09 (s, 3H).

後処理

  1. customThe solvents were evaporated to dryness under high vacuum
  2. stirringThe mixture was stirred at room temperature overnight
  3. customThe solvent was removed by rotary evaporation
  4. customThe crude product was purified by reverse phase HPLC

出典と根拠

ORDレコード
ord-b5e428389d1348e0866da00bc48ab4b4
出典データセット
uspto-grants-2016_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09238646B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート